Latest News

Argent BioPharma and AusCann enter heads of agreement for cannabinoid drug development April 15, 2025

Argent BioPharma (ASX:RGT) and AusCann have signed a strategic heads-of-agreement to advance cannabinoid-based pharmaceutical development.

Botanix secures commitments for $40 million to accelerate Sofdra rollout April 15, 2025

Botanix Pharmaceuticals (ASX:BOT) has received commitments from a significant number of new leading Australian and international institutional investors, alongside key existing institutional and sophisticated investors, to raise $40 million.

Carina Biotech completes $5 million capital raise April 15, 2025

Cell therapy immuno-oncology company Carina Biotech has reported a successful $5 million capital raise from existing and new shareholders.

Noxopharm announces SOF-SKN successfully passes final pre-trial study April 15, 2025

Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has passed its final in vivo preclinical safety study before regulatory submission for the upcoming HERACLES clinical trial.

Neuren confirms primary endpoints for Phase 3 Trial of NNZ-2591 in PMS April 15, 2025

Neuren Pharmaceuticals (ASX:NEU) has announced that the primary endpoints for its planned single Phase 3 pivotal clinical trial of NNZ-2591 in Phelan-McDermid syndrome have been confirmed at a Type C Meeting with the US FDA.

Recce announces placement and entitlement offer to support late-stage trial April 10, 2025

Recce Pharmaceuticals (ASX:RCE) has announced a significant capital raise to support Phase 3 topical clinical trials in Indonesia and Australia.

Prescient Therapeutics announces the appointment of new non-executive director April 10, 2025

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the appointment of Melanie Farris to the board as an independent non-executive director.

Opthea updates investors, confirming significant staff reduction April 10, 2025

Opthea (ASX:OPT) has updated investors following the recent termination of its COAST (Combination of OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab) Phase 3 clinical trials.

WEHI says study puts first long COVID treatment on horizon April 10, 2025

Researchers at the Walter and Eliza Hall Institute of Medical Research have shown that a new drug compound can prevent long COVID symptoms in mice.

Osteopore secures European approval for custom orthopaedic and cranial implants April 10, 2025

Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has secured market approvals for its custom orthopaedic and cranial implants in Europe.

Universal hepatitis B testing needed to stop rise in liver cancer deaths April 8, 2025

Hepatitis Australia is calling for a nationwide rollout of the universal offer of hepatitis B testing for people aged over 25.

Alterity Therapeutics announces the completion of placement April 8, 2025

Alterity Therapeutics (ASX:ATH) has announced the completion of the second tranche of the two-tranche placement initiated earlier this year.

Most Read

Botanix secures commitments for $40 million to accelerate Sofdra rollout

Carina Biotech completes $5 million capital raise

Neuren confirms primary endpoints for Phase 3 Trial of NNZ-2591 in PMS

Argent BioPharma and AusCann enter heads of agreement for cannabinoid drug development

Noxopharm announces SOF-SKN successfully passes final pre-trial study

New Stories

Argent BioPharma and AusCann enter heads of agreement for cannabinoid drug development

Botanix secures commitments for $40 million to accelerate Sofdra rollout

Carina Biotech completes $5 million capital raise

Noxopharm announces SOF-SKN successfully passes final pre-trial study

Neuren confirms primary endpoints for Phase 3 Trial of NNZ-2591 in PMS

Recce announces placement and entitlement offer to support late-stage trial

Prescient Therapeutics announces the appointment of new non-executive director

Sign In

Most Read

Botanix secures commitments for $40 million to accelerate Sofdra rollout

Carina Biotech completes $5 million capital raise

Neuren confirms primary endpoints for Phase 3 Trial of NNZ-2591 in PMS

Argent BioPharma and AusCann enter heads of agreement for cannabinoid drug development

Noxopharm announces SOF-SKN successfully passes final pre-trial study

Follow Us

New Stories

Argent BioPharma and AusCann enter heads of agreement for cannabinoid drug development

Botanix secures commitments for $40 million to accelerate Sofdra rollout

Carina Biotech completes $5 million capital raise

Noxopharm announces SOF-SKN successfully passes final pre-trial study

Neuren confirms primary endpoints for Phase 3 Trial of NNZ-2591 in PMS

Recce announces placement and entitlement offer to support late-stage trial

Prescient Therapeutics announces the appointment of new non-executive director